The Wegovy Golden Dose: What Patients Are Really Asking

Where the 'golden dose' idea comes from, and why it holds up

The phrase did not come from a clinical paper. It spread through patient forums and social media as people compared notes on which point in the schedule felt transformative. But dismissing it as anecdote misses something the data supports: semaglutide has a clear dose-response relationship, meaning more medicine generally produces more appetite suppression and more weight loss, up to the licensed ceiling.

In the STEP 1 trial (68 weeks, over 1,900 adults with obesity or overweight and at least one weight-related condition) participants reached an average of roughly 15% body-weight reduction at the 2.4 mg maintenance dose, compared with around 2.4% on placebo, as published in the New England Journal of Medicine. That headline figure was reached only after the full titration; earlier doses produced progressively less. So the feeling that 'something changed' at a higher step is not imagined, it reflects how the medicine works.

For most people sharing experiences online, 1.0 mg or 1.7 mg tends to be the dose they describe as the moment it 'clicked'. Others find 2.4 mg the step that made the difference. Neither answer is universal, and your own physiology, starting weight and tolerability all shift where that threshold sits.

What the 7.2 mg approval adds to the picture

Until early 2026 the question of whether there was a golden dose above 2.4 mg was theoretical. Then, on 12 January 2026, the MHRA approved a 7.2 mg maintenance dose of Wegovy for adults with a BMI of 30 or above, and on 14 April 2026 a dedicated single-dose 7.2 mg pen followed, as confirmed in the MHRA's announcement on GOV.UK. Trials reported an average weight loss of around 20.7% over 72 weeks at this higher level, closing the gap with tirzepatide results considerably.

That changes the conversation. If 1.7 mg was your 'golden' point, it is worth knowing that the licensed schedule now goes further. Whether reaching 7.2 mg is appropriate, and how long titration takes to get there, is exactly the kind of question a prescriber works through with you over time. Our overview of the full Wegovy dose schedule sets out each step factually if you want the complete picture before your consultation.

A question our prescribers hear most weeks: 'Can I just stay at this dose forever because it's working?' The answer is nuanced. Staying at a tolerated, effective dose is clinically reasonable; moving higher may offer additional benefit; neither decision should be made unilaterally. The prescriber reviews both the evidence of progress and your experience of side effects at every stage.

Side effects, tolerability and the dose you can actually sustain

Part of why the golden dose concept resonates is that it implicitly involves a trade-off: a dose high enough to suppress appetite meaningfully, but not so high that nausea or digestive discomfort makes daily life difficult. That trade-off is real, and the titration schedule exists precisely to navigate it.

The most common side effects of Wegovy are gastrointestinal: nausea, loose stools, constipation, reflux and fatigue. These tend to peak around a dose increase and settle over the following days to two weeks, as described on the NHS semaglutide medicines page. For some people, side effects at 2.4 mg prompt a return to 1.7 mg; for others, 2.4 mg is well-tolerated from the first pen. Your prescriber can advise on slowing titration or adjusting if needed, the licensed schedule sets the framework, not a rigid timetable.

If you are looking at the practical side of managing Wegovy pens alongside dose changes, the guide on how to use a Wegovy pen at each dose covers injection technique and what to expect step by step. For context on how Wegovy's titration compares to what the treatment generally involves, the Wegovy treatment overview is a sensible starting point.

How a prescriber approaches dose decisions, and what this means for you

There is no shortcut here, and that is not a bureaucratic obstacle. Dose escalation for a prescription medicine is reviewed clinically because the right dose depends on things a website cannot know: how much weight you have lost so far, what side effects you are experiencing, your other medicines, and your overall health picture. If you are still at the beginning of the schedule, our step-by-step guide to injecting your first 0.25 mg dose walks you through exactly what to expect from the very first injection. The deeper look at whether a defined golden dose exists in Wegovy explores the evidence behind the concept in more detail.

Cost is sometimes a factor in dose conversations too, higher-dose pens carry higher list prices, and the Wegovy price comparison for UK patients sets out what private treatment costs look like across the schedule, so you can plan without surprises.

At nume, every Wegovy consultation is read personally by a GPhC-registered Independent Prescriber on the day it is submitted. Dose increases require a clinical review of your progress, not an automatic refill. That process is slower than a checkout button, and intentionally so. If you are ready to explore whether Wegovy is appropriate for you, start your free consultation and a prescriber will take it from there.